Bryostatin-1 and IFN-γ synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages

Cancer Research

Volumn 57, Issue 12, 1997, Pages 2468-2473

  Taylor, Lynn S ^a   Cox, George W ^a   Melillo, Giovanni ^a   Bosco, Maria Carla ^a   Espinoza Delgado, Igor ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; GAMMA INTERFERON; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME MODIFICATION; GENE EXPRESSION REGULATION; HEMATOPOIETIC CELL; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN PROCESSING; STEM CELL; TRANSCRIPTION REGULATION;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERFERON TYPE II; LACTONES; MACROLIDES; MACROPHAGES; MICE; MITOGENS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030907108     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Pettit, G. R., Herald, C. L., Doubek, D. L., and Herald, D. L. Isolation and structure of bryostatin-1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
2. Pettit, G. R., Day, J. F., Hartwell, J. L., and Wood, H. B. Antineoplastic components of marine animals. Nature (Lond.), 227: 962-963, 1970.
3. Schuchter, L. M., Esa, A. H., May, W. S., Laulis, M. K., Pettit, G. R., and Hess, A. D. Successful treatment of murine melanoma with bryostatin-1. Cancer Res., 51: 682-687, 1991.
4. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostalin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
5. Pettit, G. R. The bryostatins. In: W. Herz., G. W. Kirby, W. Steglich, and C. Tamm (eds.), Progress in the Chemistry of Organic Natural Products, pp. 153-195. Vienna: Springer-Verlag, 1991.
6. Kennedy, M. J., Prestigiacomo, L. J., Tyler, G., May, W. S., and Davidson, N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res., 52: 1278-1283, 1992.
7. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk. Res., 17: 1-8, 1993.
8. Scheid, C., Prendiville, J., Jayson, G., Crowther, D., Fox, B., Pettit, G. R., and Stern, P. L. Immtmomodulation in patients receiving intravenous bryostatin-1 in a Phase I clinical study: comparison with effects of bryostatin-1 on lymphocyte function in vitro. Cancer Immunol. Immunother., 12: 223-230, 1994.
9. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGowan, A., Testa, N., Stern, P. L., McDermott, R., Potter, M., and Pettit, G. R. A Phase I clinical study of intravenous bryostatin-1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
10. Pluda, J. M., Cheson, B. D., and Phillips, P. H. Clinical trials referral resource. Oncology, 10: 740-742, 1995.
11. Eisemann, K., Totola, A., Jurcic, K., Pettit, G. R., and Wagner, H. Bryostatins 1, 2, and 5 activate human granulocytes and lymphocytes: in vitro and in vivo studies. Pharm. Pharmacol. Lett., 1: 45-48, 1995.
12. Berkow, R. L., Schlabach, L., Dodson, R., Benjamin, W .H., Pettit, G. R., Rustagi, P., and Kraft, A. S. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res., 53: 2810-2815, 1993.
13. Stone, R. M., Sariban, E., Pettit, G. R., and Kufe, D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood, 72: 208-213, 1988.
14. Lilly, M., Tompkins, C., Brown, C., Pettit, G. R., and Kraft, A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res., 50: 5520-5525, 1990.
15. May, W. S., Sharkis, S. J., Esa, A. H., Gebbia, V., Kraft, A. S., Pettit, G. R., and Sensenbrenner, L. L. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA, 84: 8483-8487, 1987.
16. Sharkis, S. J., Jones, R. J., Bellis, M. L., Demelri, G. D., Griffin, J. D., Civin, C., and May, W. S. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood, 76: 716-720, 1990.
17. Gebbia, V., Testa, A., Pettit, G. R., Sensenbrenner, L. L., and May, W. S. Antineoplastic agent bryostatin-1 promotes growth of normal murine haematopoietic progenitors in vivo Cell. Pharm., 1: 31-35, 1993.
18. Steube, K. G., and Drexler, H. G. The protein kinase C activator bryostatin-1 induces the rapid release of TNFα from MONO-MAC 6 cells. Biochem. Biophys. Res. Commun., 214; 1197-1203, 1995.
19. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F., and Harris, A. L. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J. Natl. Cancer Inst., 85: 1812-1818, 1993.
20. Snyder, S. H., and Bredt, D. S. Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci., 12: 125-128, 1991.
21. Radomski, M. W., Palmer, R. M. J., and Moncada, S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun., 148: 1482-1489, 1987.
22. Radomski, M. W., Palmer, R. M. J., and Moncada, S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol., 92: 639-646, 1987.
23. Ignarro, L. J. Endothelium-derived nitric oxide: actions and properties. FASEB J., 3: 31-36, 1989.
24. Moncada, S., Palmer, R. M. J., and Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43: 109-142, 1991.
25. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J., 6: 3051-3064, 1992.
26. Lowenstein, C. J., Glatt, C. S., Bredt, D. S., and Snyder, S. H. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl. Acad. Sci. USA, 89: 6711-6715, 1992.
27. Xie, Q-W., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., and Nathan, C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (Washington DC), 256: 225-228, 1992.
28. Lyons, C. R., Orloff, G. J., and Cunningham, J. M. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J. Biol. Chem., 267: 6370-6374, 1992,
29. Sessa, W. C. Harrison, J. K., Barber, C. M., Zeng, D., Durieux, M. E., D'Angelo, D. D., Lynch, K. R., and Peach, M. J. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J. Biol. Chem., 267: 15274-15276, 1992.
30. Lamas, S., Marsden, P. A., Li, G. K., Tempst, P., and Michel, T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive isoform. Proc. Natl. Acad. Sci. USA, 89: 6348-6352, 1992.
31. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature (Lond.), 351: 714-718, 1991.
32. Ding, A. H., Nathan, C. F., and Stuehr, D. J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison ot activating cytokines and evidence for independent production. J. Immunol., 141: 2407-2412, 1988.
33. Cox, G. W., Melillo, G., Chattopadhyay, U., Mullet, D., Fertel, R. H., and Varesio, L. Tumor necrosis fact or-α-dependent production of reactive nitrogen intermediates mediates IFN-G plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol., 149: 3290-3296, 1992.
34. Melillo, G., Cox, G. W., Radzioch, D., and Varesio, L. Picolinic acid, a calabolite of L-tryplophan, is a costimulus for the induction of reactive nitrogen intermediate production in murine macrophages. J. Immunol., 150: 4031-4040, 1993.
35. Melillo, G., Cox, G. W., Biragyn, A., Sheffler, L. A., and Varesio, L. Regulation of nitric-oxide synthase mRNA expression by interferon-γ and picolinic acid. J. Biol. Chem., 269: 8128-8133, 1994.
36. Drapier, J. C., Wietzerbin, J., and Hibbs, J. B., Jr. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol., 18: 1587-1592, 1988.
37. Bonta, I. L., and Ben-Efraim, S. Involvement of inflammatory mediators in macrophage antitumor activity. J. Leuk. Biol., 54: 613-626, 1993.
38. Blasi, E., Radzioch, D., Durum, S. K., and Varesio, L. A murine macrophage cell line. immortalized by v-raf and v-myc oncogenes, exhibits normal macrophage functions. Eur. J. Immunol., 17: 1491-1498, 1987.
39. Cox, G. W., Mathieson, B. J., Gandino, L., Biasi, E., Radzioch, D., and Varesio, L. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J. Natl. Cancer Inst., 81: 1492-1496, 1989.
40. Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S., and Cerami, A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA, 83: 1670-1674, 1986.
41. Golub, E. I., Kim, H., and Volsky, D. J. Transfection of DNA into adherent cells by DEAE-dextran/DMSO method increases drastically if the cells are removed from surface and treated in suspension. Nucleic Acids Res., 17: 4902-4906, 1989.
42. Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., and Varesio, L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med., 182: 1683-1693, 1995.
43. Gorman, C. M., Moffat, L. F., and Howard, B. H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol., 2: 1044-1047, 1982.
44. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
45. Xie, Q-W., Whisnant, R., and Nathan, C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide. J. Exp. Med., 177: 1779-1784, 1993.
46. Lowenstein, C. J., Alley, E. W., Raval, P., Snowman, A. M., Snyder, S. H., Russell, S. W., and Murphy, W. J. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide. Proc. Natl. Acad. Sci. USA, 90: 9730-9734, 1993.
47. Bosco, M. C., Rottschafer, S., Taylor, L. S., Ortaldo, J. R., Longo, D. L., and Espinoza-Delgado, I. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with IL-2 and modulation of IL-2R gamma chain expression. Blood, 89: 3402-3411, 1997.
48. Grant, S., Poplin, B., Bear, H. D., Tombes, M. B., Kyle, B. M., and Roberts, J. Phase Ib pharmakinetic and pharmacodynamic trial of the protein kinase C activator bryostatin-1. Proc. Am. Assoc. Cancer Res., 37: 1146, 1996.
49. Martin, E., Nathan, C., and Xie, Q-W. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med., 180: 977-984, 1994.
50. Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H., and Russell, S. W. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J. Biol. Chem., 268: 1908-1913, 1993.
51. Xie, Q-W., Kashiwabara, Y., and Nathan, C. Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J. Biol. Chem., 269: 4705-4708, 1994.
52. Wang, Y., and Marsden, P. A. Nitric oxide synthases: gene structure and regulation. In: L. Ignarro and F. Murad (eds.), Nitric Oxide Biochemistry, Molecular Biology, and Therapeutic Implications, pp. 71-90. San Diego: Academic Press, 1996.
53. Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q-W., and Nathan, C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J. Exp. Med., 178: 605-613, 1993.
54. Weisz, A., Oguchi, S., Cicatiello, L., and Esumi, H. Dual mechanism for the control of inducible-type NO synthase gene expression in macrophages during activation by interferon-γ and bacterial lipopolysaccharide. J. Biol. Chem., 269: 8324-8333, 1994.
55. Jun, C., Choi, B., Ryu, H., Um, J., Kwak, H., Lee, B., Paik, S., Kim, H., and Chung, H. Synergistic cooperation between phorbol ester and IFN-γ for induction of nitric oxide synthesis in murine peritoneal macrophages. J. Immunol., 153: 3684-3690, 1994.
56. Lieberman, A. P., Pitha, P. M., and Shin, M. L. Protein kinase regulates tumor necrosis factor mRNA stability in virus-stimulated astrocytes. J. Exp. Med., 172: 989-992, 1990.
57. Lieberman, A. P., Pitha, P. M., and Shin, M. L. Poly(A) removal is the kinase-regulated step in tumor necrosis factor mRNA decay. J. Biol. Chem., 267: 2123-2126, 1992.
58. Berkow, R. L., and Kraft, A. S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem. Biophys. Res. Commun., 131: 1109-1116, 1985.
59. 3H]bryostatin 4 to protein kinase C. Biochem. Pharmacol., 43: 2007-2014, 1992.
60. Szallasi, Z., Du, L., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., and Blumberg, P. M. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res., 56: 2105-2111, 1996.
61. Lui, S., Reichner, J. S., Mateo, R. B., and Albina, J. E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or independent mechanisms. Cancer Res., 54: 2462-2467, 1994.
62. Hibbs, J. B., Jr., Taintor, R. R., and Vavrin, Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science (Washington DC), 235: 473-476, 1987.
63. Hibbs, J. B., Jr., Vavrin, Z., and Taintor, R. R. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J. Immunol., 138: 550-565, 1987.
64. Kwon, N. S., Stuehr, D. J., and Nathan, C. F. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J. Exp. Med., 174: 761-767, 1991.
65. Hibbs, J. B., Jr., Taintor, R. R., Vavrin, Z., and Rachlin, E. M. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun., 157: 87-94, 1988.
66. Drapier, J. C., Pellat, C., and Yann, H. Generation of EPR-detectable iron-nitrosyl complexes in tumor target cells cocultured with activated macrophages. J. Biol. Chem., 266: 10162-10167, 1991.
67. Thomsen, L. L., Baguley, B. C., Rustin, G. J. S., and O'Reilly, S. M. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma II: induction of nitric oxide production. Br. J. Cancer, 66: 723-727, 1992.
68. DiNapoli, M. R., Calderon, C. L., and Lopez, D. M. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J. Exp. Med., 183: 1323-1329, 1996.